Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

NCT ID: NCT01625338

Last Updated: 2015-11-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

534 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) in combination with ribavirin (RBV) with or without pegylated interferon (Peg-IFN) in adults with chronic hepatitis C virus (HCV) infection who participated in a prior Gilead HCV study and have not achieved sustained virologic response (SVR).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SOF+RBV 12 Weeks

SOF+RBV for 12 weeks

Group Type EXPERIMENTAL

SOF

Intervention Type DRUG

SOF 400 mg tablet administered orally once daily

RBV

Intervention Type DRUG

RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

SOF+RBV 24 Weeks

SOF+RBV for 24 weeks

Group Type EXPERIMENTAL

SOF

Intervention Type DRUG

SOF 400 mg tablet administered orally once daily

RBV

Intervention Type DRUG

RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

SOF+RBV+Peg-IFN 12 Weeks

SOF+RBV+Peg-IFN for 12 weeks

Group Type EXPERIMENTAL

SOF

Intervention Type DRUG

SOF 400 mg tablet administered orally once daily

RBV

Intervention Type DRUG

RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Peg-IFN

Intervention Type DRUG

Peg-IFN 180 μg administered once weekly by subcutaneous injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SOF

SOF 400 mg tablet administered orally once daily

Intervention Type DRUG

RBV

RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention Type DRUG

Peg-IFN

Peg-IFN 180 μg administered once weekly by subcutaneous injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sovaldi® GS-7977 PSI-7977

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infection with HCV
* Must have participated in a prior Gilead HCV study
* Use of highly effective contraception methods if female of childbearing potential or sexually active male
* Eligible patients include those in the following

* received placebo or Peg-IFN+RBV in a control arm
* previously participated in a Gilead-sponsored HCV study and did not attain sustained virologic response 24 weeks after discontinuation of therapy (SVR24) on a regimen containing:

* Sofosbuvir+RBV
* Peg-IFN and/or RBV in combination with one or more Gilead investigational direct-acting agents

Exclusion Criteria

* Pregnant or nursing female or male with pregnant female partner
* Current or prior history of clinical hepatic decompensation
* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
* Chronic use of systemically administered immunosuppressive agents
* Active drug abuse
* Use of any prohibited concomitant medications
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gilead Sciences

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bittoo Kanwar, MD

Role: STUDY_DIRECTOR

Gilead Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Franco Felizarta, MD

Bakersfield, California, United States

Site Status

Arrowhead Regional Medical Center

Colton, California, United States

Site Status

Southern California Transplantation Institute, Research Foundation Liver Center

Coronado, California, United States

Site Status

eStudy Site

La Mesa, California, United States

Site Status

Kaiser Permanente

Los Angeles, California, United States

Site Status

Lightsource Medical/Peter J. Ruane MD, Inc.

Los Angeles, California, United States

Site Status

California Liver Institute

Los Angeles, California, United States

Site Status

Anthony Mills MD, Inc.

Los Angeles, California, United States

Site Status

eStudySite

Oceanside, California, United States

Site Status

University of California Davis Medical Center

Sacramento, California, United States

Site Status

University of California

San Diego, California, United States

Site Status

Resarch and Education, Inc.

San Diego, California, United States

Site Status

Medical Associates Research Group

San Diego, California, United States

Site Status

Kaiser Permanente

San Diego, California, United States

Site Status

Quest Clinical Research

San Francisco, California, United States

Site Status

University of Colorado Hospital

Aurora, Colorado, United States

Site Status

South Denver Gastroenterology, PC

Englewood, Colorado, United States

Site Status

Whitman-Walker Health

Washington D.C., District of Columbia, United States

Site Status

Pointe West Infectious Diseases d/b/a Bach and Godofsky Infectious Diseases

Bradenton, Florida, United States

Site Status

University of Florida

Gainesville, Florida, United States

Site Status

Borland-Groover Clinic

Jacksonville, Florida, United States

Site Status

University of Miami Center for Liver Diseases

Miami, Florida, United States

Site Status

Orlando Immunology Center

Orlando, Florida, United States

Site Status

Internal Medicine Specialists

Orlando, Florida, United States

Site Status

Advanced Research Institute

Trinity, Florida, United States

Site Status

South Florida Center of Gastroenterology, PA.

Wellington, Florida, United States

Site Status

Atlanta Gastroenterology Associates, LLC

Atlanta, Georgia, United States

Site Status

Digestive Healthcare of Georgia

Atlanta, Georgia, United States

Site Status

Gastointestinal Specialists of Georgia, PC

Marietta, Georgia, United States

Site Status

Indianapolis Gastroenterology Research Foundation

Indianapolis, Indiana, United States

Site Status

Digestive Disease Associates, PA

Baltimore, Maryland, United States

Site Status

Johns Hopkins University

Lutherville, Maryland, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Infectious Disease and The Research Institute

Springfield, Massachusetts, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

Orlando Clinical

Novi, Michigan, United States

Site Status

Minnesota Gastroenterology, P.A.

Saint Paul, Minnesota, United States

Site Status

Kansas City Gastroenterology and Hepatology

Kansas City, Missouri, United States

Site Status

ID Care, Inc.

Hillsborough, New Jersey, United States

Site Status

AGA Clinical Research Associates, LLC

Township, New Jersey, United States

Site Status

The Gastroenterology Group of South Jersey

Vineland, New Jersey, United States

Site Status

Binghamton Gastroenterology Associates, PC

Binghamton, New York, United States

Site Status

North Shore University Hospital

Manhasset, New York, United States

Site Status

Weill Cornell Medical College

New York, New York, United States

Site Status

Mount Sinai School of Medicine

New York, New York, United States

Site Status

Clinical Study Center of Asheville, LLC

Asheville, North Carolina, United States

Site Status

University of North Carolina

Chapel Hill, North Carolina, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Carolinas Center for Liver Disease

Statesville, North Carolina, United States

Site Status

Digestive Health Specialists, PA

Winston-Salem, North Carolina, United States

Site Status

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

University Gastroenterology

Providence, Rhode Island, United States

Site Status

Gastro One

Germantown, Tennessee, United States

Site Status

Memphis Gastroenterology Group, PC

Germantown, Tennessee, United States

Site Status

Nashville Medical Research Institute

Nashville, Tennessee, United States

Site Status

Texas Clinical Research Institute, LLC

Arlington, Texas, United States

Site Status

Annette C. and Harold C. Simmons Transplant Center

Dallas, Texas, United States

Site Status

Research Specialists of Texas

Houston, Texas, United States

Site Status

Alamo Medical Research

San Antonio, Texas, United States

Site Status

Metropolitan Research

Fairfax, Virginia, United States

Site Status

Inova Fairfax Hospital

Falls Church, Virginia, United States

Site Status

Bon Secours Saint Mary's Hospital of Richmond

Newport News, Virginia, United States

Site Status

Digestive and Liver Disease Specialists

Norfolk, Virginia, United States

Site Status

Virginia Mason Medical Center

Seattle, Washington, United States

Site Status

Concord Repatriation General Hospital

Concord, New South Wales, Australia

Site Status

Westmead Hospital

Westmead, New South Wales, Australia

Site Status

Gallipoli Medical Research Foundation

Greenslopes, Queensland, Australia

Site Status

Royal Adelaide Hospital

Adelaide, South Australia, Australia

Site Status

Austin Hospital

Heidelberg, Victoria, Australia

Site Status

Monash Medical Centre

Melbourne, Victoria, Australia

Site Status

B2 Clinic

Fremantle, Western Australia, Australia

Site Status

Canberra Hospital

Australian Capital Territory, , Australia

Site Status

St. Vincent's Hospital

Fitzroy, , Australia

Site Status

Royal Brisbane & Women's Hospital

Herston, , Australia

Site Status

St George Hospital

Kogarah, , Australia

Site Status

Royal Prince Alfred Hospital, Camperdown

NSW, , Australia

Site Status

Royal Perth Hospital

Perth Western Australia, , Australia

Site Status

Princess Alexandra Hospital

State of Queensland, , Australia

Site Status

Box Hill Hospital

Victoria, , Australia

Site Status

Medizinische Universität Graz

Graz, , Austria

Site Status

Medizinische Universität Wien

Vienna, , Austria

Site Status

Wilhelminenspital

Vienna, , Austria

Site Status

University of Calgary

Calgary, Alberta, Canada

Site Status

University of Alberta Hospital

Edmonton, Alberta, Canada

Site Status

Vancouver Infectious Disease Research and Care Centre

Vancouver, British Columbia, Canada

Site Status

Gastrointestinal Research Institute (GIRI)

Vancouver, British Columbia, Canada

Site Status

John Buhler Research Center

Winnipeg, Manitoba, Canada

Site Status

Mount Sinai Hospital

Toronto, Ontario, Canada

Site Status

Toronto Western Hospital

Toronto, Ontario, Canada

Site Status

Toronto Western Hospital

Toronto, Ontario, Canada

Site Status

Toronto Liver Centre

Toronto, Ontario, Canada

Site Status

Toronto Digestive Diseases Associates, Inc

Vaughan, Ontario, Canada

Site Status

Hopital St. Luc

Montreal, Quebec, Canada

Site Status

Gordon & Leslie Diamond Health Care Centre

Vancouver, , Canada

Site Status

Remedis s.r.o., Nestátní zdravotnické zarízení

Prague, , Czechia

Site Status

West Tallinn Central Hospital

Tallinn, , Estonia

Site Status

Tartu University Hospital

Tartu, , Estonia

Site Status

Centre Hospitalier Universitaire de Clermont-Ferrand

Clermont-Ferrand, , France

Site Status

CHU Estaing

Clermont-Ferrand, , France

Site Status

Hôpital Beaujon

Clichy, , France

Site Status

Hôpital Henri Mondor

Créteil, , France

Site Status

Hôpital Claude Huriez- Service d'Hépato-Gastroentérologie

Lille, , France

Site Status

Hôpital Saint Joseph

Marseille, , France

Site Status

Hopital Saint Eloi

Montpellier, , France

Site Status

Service Hepatologie

Nice, , France

Site Status

Hôpital Saint-Antoine

Paris, , France

Site Status

Groupe Hospitalier Pitié-Salpétrière

Paris, , France

Site Status

Hôpital Haut-Lévêque, CHU Bordeaux

Pessac, , France

Site Status

Centre Hospitalier Universitare de Rennes, Hôpital Pontchaillou

Rennes, , France

Site Status

Centre Hospitalier Universitaire de Strasbourg

Strasbourg, , France

Site Status

Hopital de I'Archet 2

Vandœuvre-lès-Nancy, , France

Site Status

Leber- und Studienzentrum am Checkpoint

Berlin, , Germany

Site Status

Campus Virchow Klinikum

Berlin, , Germany

Site Status

Universitätsklinikum Bonn

Bonn, , Germany

Site Status

Universitätsklinikum Düsseldorf

Düsseldorf, , Germany

Site Status

Klinikum und Fachbereich Medizin Johann Wolfgang Goethe-Universität Frankfurt am Main

Frankfurt am Main, , Germany

Site Status

PraxisZentrum für Gastroenterologie und Endokrinologie

Freiburg im Breisgau, , Germany

Site Status

Asklepios Klinik Sankt Georg Hamburg

Hamburg, , Germany

Site Status

Universitätsklinikum Hamburg Eppendorf

Hamburg, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

Medizinische Universitätsklinik IV (Krehl Klinik) Abt. Gastroenterologie und Infektionskrankheiten

Heidelberg, , Germany

Site Status

Gastroenterologische Gemeinschaftspraxis

Herne, , Germany

Site Status

Leberstudienzentrum Kiel

Kiel, , Germany

Site Status

Universitätsklinikum Leipzig

Leipzig, , Germany

Site Status

Klinikum der Universität München

Munich, , Germany

Site Status

Centrum fur Interdisziplinare Medizin

Münster, , Germany

Site Status

Universitatsklinikum Wurzburg

Würzburg, , Germany

Site Status

Casa Sollievo della Sofferenza Hospital

San Giovanni Rotonda, Foggia, Italy

Site Status

Ospedale S. Annunziata

Florence, , Italy

Site Status

Ente Ospedaliero Ospedali Galliera di Genova

Genoa, , Italy

Site Status

Azienda Ospedaliera Ospedale Niguarda Ca' Granda

Milan, , Italy

Site Status

Fondazione IRCCS CA Granada - Ospedale Maggiore Policlinico

Milan, , Italy

Site Status

Azienda Ospedaliera de Padova

Padua, , Italy

Site Status

Azienda Ospedaliero Universitaria di Parma

Parma, , Italy

Site Status

Fondazione PTV - Policlinico Tor Vergata

Roma, , Italy

Site Status

I.N.M.I L. Spallanzani IRCCS

Rome, , Italy

Site Status

Azienda Ospedaliero Universitaria S. Giovanni Battista di Torino

Turin, , Italy

Site Status

Academisch Medisch Centrum

Amsterdam, , Netherlands

Site Status

Radboud University Nijmegen Medical Centre (UMC St Radboud)

Nijmegen, , Netherlands

Site Status

Academic Hospital Rotterdam Erasmus Medical Center

Rotterdam, , Netherlands

Site Status

Auckland Clinical Studies

Grafton, Auckland, New Zealand

Site Status

Tauranga Hospital

Tauranga, BOP, New Zealand

Site Status

Christchurch Hospital

Christchurch, Christchurch, New Zealand

Site Status

Wellington Hospital

Newtown, WGN, New Zealand

Site Status

Auckland City Hospital

Auckland, , New Zealand

Site Status

Dunedin Hospital

Dunedin, , New Zealand

Site Status

Waikato Hospital

Hamilton, , New Zealand

Site Status

Klinika Chorob Zakaznych i Hep

Bialystok, , Poland

Site Status

Oddzial Kliniczny Chorob Zakaznych

Chorzów, , Poland

Site Status

WSSzpital im.Dr.Wj.Bieganskieg

Lodz, , Poland

Site Status

ID Clinic

Mysłowice, , Poland

Site Status

Sp Zoz Wojewódzki Szpital

Warsaw, , Poland

Site Status

Fundacion De Investigacion De Diego

San Juan, PR, Puerto Rico

Site Status

Hospital Casa de la Maternidad

Barcelona, , Spain

Site Status

Hospital Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Carlos III

Madrid, , Spain

Site Status

Hospital Puerta de Hierro Majadahonda

Majadahonda, , Spain

Site Status

Hospital Clinico Universitario Virgen de la Victoria

Málaga, , Spain

Site Status

Hospital Universitario Nuestra Señora de Valme

Seville, , Spain

Site Status

Hospital General Universitario de Valencia

Valencia, , Spain

Site Status

Sahlgrenska University Hospital

Gothenburg, , Sweden

Site Status

Skånes Universitetssjukhus, Malmö

Malmo, , Sweden

Site Status

Karolinska University Hospital Huddinge

Stockholm, , Sweden

Site Status

The Liver Unit

Paddington, London, United Kingdom

Site Status

University of Birmingham

Birmingham, , United Kingdom

Site Status

Southampton University Hospital

Hampshire, , United Kingdom

Site Status

London Royal Hospital, GHU

London, , United Kingdom

Site Status

King's College Hospital

London, , United Kingdom

Site Status

Chelsea and Westminster Hospital NHS Foundation Trust

London, , United Kingdom

Site Status

Royal Free Hospital and University College London Hospital

London, , United Kingdom

Site Status

North Manchester General Hospital

Manchester, , United Kingdom

Site Status

Nottingham University Hospitals-NHS

Nottingham, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Canada Czechia Estonia France Germany Italy Netherlands New Zealand Poland Puerto Rico Spain Sweden United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-000571-16

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

GS-US-334-0109

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase 3 Study of Sofosbuvir and Ribavirin
NCT01497366 COMPLETED PHASE3